$PSGR Well, Pershing Resources has a new COO and events are rapidly coming to a boil! Let's review what is happening...Donald Trump is the President-elect for the US. Putin is still in power in Russia. Winter is coming to the Northern Hemisphere. The Sun rises in the East and sets in the West. No information from Pershing Resources with respect to mine operations, productivity or, precious metals. Yep, the reports from around the World continue to be updated on, at a minimum, a daily basis...then there is Pershing Resources. The latest Press Release provides volumes of information to the shareholders and potential investors. Uh-huh, we now know that corporate personnel are alive snd switching positions. We now know that something, some time, somewhere may possibly occur that could possibly impact the minesite(s)......or not. I am so overwhelmed with the knowledge provided by the latest Press Release that I envision tens of MILLIONS of investors rushing to their computers or stockbrokers and buying TRILLIONS of PSGR shares...no, not really...just kidding!!! I am so UNDERWHELMED by the latest Press Release that I envision another RAH-RAH Press Release coming out and stating that 'Winter conditions will prevent us from further developing the Arizona and Nevada minesites. We anticipate that mining DEVELOPMENT operations will continue once weather conditions return to warmer temperatures. At that time we will introduce our latest and greatest, never been tested or tried before, it might work technology to add to the mining circuit that is still being developed to produce a yet to be mined or identified precious metal that may (or may not) exist at the Arizona and Nevada claim sites.'...or words go that effect. You may want to locate some coal to put in your Christmas Stockings that are hanging on your mantels. I don't foresee any (ahem) precious metals in Santa's bag.
$PSGR Well, Pershing Resources has a new COO and events are
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Investors Urged to Act as Lawsuit Against Everus Builds
Investigation of Claims Against Everus Construction Group Faruqi & Faruqi, LLP, a well-respected national securities law firm, has initiated an investigation into potential claims associated with Everus Construction Group, Inc. (NYSE: ECG). The firm specializes in shareholder rights and is aiming to provide support to affected investors after concerning revelations about...
Continue Reading
Heilongjiang Forum 2025: Elevating Macao's Global Tourism Standing
Global Tourism Economy Forum 2025: A Landmark Event The Global Tourism Economy Forum (GTEF) made its notable debut outside of Macao by hosting the 2025 edition in Heilongjiang province, China. This forum gathered influential figures from the tourism sector and various related industries, fostering discussions aimed at exploring new avenues for cooperation and growth....
Continue Reading
Nextracker and T1 Energy Collaboration Drives Solar Growth
Nextracker and T1 Energy Join Forces to Strengthen Solar Production Nextracker Inc. (NASDAQ: NXT) has recently established a partnership with T1 Energy Inc. (NYSE: TE) aimed at revolutionizing solar manufacturing. This collaboration will see the integration of Nextracker's cutting-edge steel module frame technology into T1 Energy's upcoming solar manufacturing plant,...
Continue Reading
Nathan Ballentine Steps In as Regional VP at New American Funding
New Leadership at New American Funding New American Funding (NAF), a prominent independent mortgage lender, has announced a significant appointment. Nathan Ballentine is joining the team as the Regional Vice President, where he will play a pivotal role in propelling growth and development within the state. His expertise will be crucial as the company seeks to deepen its...
Continue Reading
CSL Behring Secures Approval for ANDEMBRY® in Japan
CSL Behring's Recent Approval for ANDEMBRY® CSL Behring has announced a significant medical milestone with the approval of ANDEMBRY® (garadacimab) subcutaneous (S.C.) injection 200mg pens in Japan. This groundbreaking therapy is a first-in-class monoclonal antibody specifically designed to inhibit activated Factor XII (FXIIa), a crucial initiator in the hereditary...
Continue Reading